Is Avalyn Pharma Inc. Common Stock (AVLN) a Buy, Sell, or Hold?
NASDAQ : AVLN
Avalyn Pharma Inc. Common Stock
$29.03 USD
$0.4 (1.4%)
- Volume
- 289.15K
- Average Volume
- 519.64K
- Market Capitalization
- $1.29B
- P/E Ratio
- -14.23
- Dividend Yield
- 0.00%
- Price Target
- $52.50
- Year High
- $33.32
- Year Low
- $24.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.19
Company Overview
NASDAQ
Lyn Baranowski
Medical - Pharmaceuticals
Healthcare
AVLN
50
US
USD
Liquidity Metrics
-0.01
10.19
10.19
3.71
0.00
Sales & Valuation
-$
0.00
-5.09
-15.73
-1.96
Profitability
-$2.04
-$85.2M
0.00%
0.00%
35.70%
-57.23%
P/E Metrics
-14.23
-0.14
-0.14
Analyst Price Target & Rating
$52.50
$80.00
$51.00
2/5
0 Analysts
-44.70%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
$1.21B
0.00
-13.28
10.19
35.70%
-67.51%
-7.16%
-6.48%
0 days
Company Executives
| Name | Title |
|---|---|
| Craig Conoscenti | Senior Vice President of Clinical Development |
| Howard Lazarus | Chief Medical Officer |
| Melissa Rhodes DABT | Chief Operating Officer |
| Stephen Pham | Senior Vice President of Product Development |
| Adam Golden | General Counsel & Head of Business Development |
| Douglas R. Carlson | CFO & Chief Business Officer |
| James Bishop | Senior Vice President of Business Operations |
| Cassie Saitow | Senior Director of IR & Corporate Communications |
| Lyn Baranowski | CEO, President & Director |
| Michelle Patterson | Senior Vice President of Corporate Planning & Portfolio Strategy |
Poll Results
No votes yet today — be the first to share your view!
About Avalyn Pharma Inc. Common Stock (NASDAQ:AVLN) Stock
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts. ...
2026-06-17 08:00:00
Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
2026-06-05 22:07:04
Avalyn Pharma NASDAQ: AVLN executives outlined the company's inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-06-03 07:00:00
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability profile
Avalyn to Participate in the Jefferies Global Healthcare Conference
2026-05-27 08:00:00
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will present a company overview at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, at 9:55-10:25 a.m. ET.
2026-05-21 08:00:00
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced an upcoming poster presentation at the European Alliance of Associations for Rheumatology (EULAR) 2026, being held June 3-6, 2026, in London, England. Updated findings from the ATLAS open-label extension trial will highlight the long-term tolerability profile of AP01 (inhaled pirfenidone) among the cohort of patients with progressive pulmonary fibrosis at up to four years of treatment.
2026-05-05 16:01:00
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced two presentations at the American Thoracic Society (ATS) 2026 International Conference being held May 15-20, 2026, in Orlando, FL.
U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market
2026-05-02 09:12:00
Four IPOs priced this past week, led by three sizable biotechs. They were joined by 11 blank check listings. Two IPOs are currently scheduled for the week ahead, though some smaller names may join the calendar late. Street research is expected for one company, and lock-up periods will be expiring for six companies.
2026-05-01 16:01:00
BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the closing of its initial public offering (IPO) of an aggregate 19,166,667 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 2,500,000 additional shares, at IPO price of $18.00 per share. All of the shares of common stock were offered by Avalyn.
Frequently Asked Questions
-
What is the current Avalyn Pharma Inc. Common Stock (AVLN) stock price?
-
Avalyn Pharma Inc. Common Stock(NASDAQ:AVLN) stock price is $29.03 in the last trading session. During the trading session, AVLN stock reached the peak price of $33.32 while $24.15 was the lowest point it dropped to. The percentage change in AVLN stock occurred in the recent session was 1.4% while the dollar amount for the price change in AVLN stock was $0.4.
-
AVLN's industry and sector of operation?
-
The NASDAQ listed AVLN is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of AVLN?
-
Craig Conoscenti | Senior Vice President of Clinical Development
Howard Lazarus | Chief Medical Officer
Melissa Rhodes DABT | Chief Operating Officer
Stephen Pham | Senior Vice President of Product Development
Adam Golden | General Counsel & Head of Business Development -
How many employees does AVLN have?
-
Number of AVLN employees currently stands at 50. AVLN operates from 105 W First St. Boston, Boston, MA 02127, US.
-
Link for AVLN official website?
-
Official Website of AVLN is: http://www.avalynpharma.com
-
How do I contact AVLN?
-
AVLN could be contacted at phone #1-206-707-0340 and can also be accessed through its website. AVLN operates from 105 W First St. Boston, Boston, MA 02127, US.
-
How many shares of AVLN are traded daily?
-
The average number of AVLN shares traded daily for last 3 months was 519.64K.
-
What is the market cap of AVLN currently?
-
The market value of AVLN currently stands at $1.29B with its latest stock price at $29.03